Suzhou Fushilai Pharmaceutical Co., Ltd. (SHE:301258)
China · Delayed Price · Currency is CNY 34.69
-0.19 (-0.54%)
At close: Feb 12, 2026
SHE:301258 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 436.1 | 426.01 | 483.1 | 548.95 | 511.66 | 466.86 |
Other Revenue | 3.46 | 3.46 | 6.19 | 19.26 | 10.03 | 9.98 |
| 439.57 | 429.47 | 489.29 | 568.21 | 521.7 | 476.85 | |
Revenue Growth (YoY) | 6.39% | -12.23% | -13.89% | 8.92% | 9.40% | 5.38% |
Cost of Revenue | 365.5 | 348.04 | 301.22 | 314.9 | 314.25 | 252.16 |
Gross Profit | 74.06 | 81.43 | 188.07 | 253.31 | 207.45 | 224.69 |
Selling, General & Admin | 41.69 | 46.58 | 50.89 | 47.65 | 37.44 | 35.32 |
Research & Development | 34.92 | 40.62 | 40.7 | 41.37 | 28.51 | 22.88 |
Other Operating Expenses | 3.57 | 1.89 | 4.78 | 5.1 | 4.11 | 4.28 |
Operating Expenses | 80.22 | 90.59 | 95.18 | 94.54 | 70.41 | 61.98 |
Operating Income | -6.15 | -9.16 | 92.89 | 158.77 | 137.04 | 162.71 |
Interest Expense | -0.07 | -0.09 | -0.12 | -0.31 | -0.45 | - |
Interest & Investment Income | 57.12 | 46.94 | 28.96 | 8.2 | 4.62 | 9.32 |
Currency Exchange Gain (Loss) | 3.36 | 3.36 | 1.48 | 31.6 | -5.5 | -6.16 |
Other Non Operating Income (Expenses) | 0.01 | -0.2 | -0.19 | -0.09 | -0.27 | -0.28 |
EBT Excluding Unusual Items | 54.27 | 40.85 | 123.02 | 198.17 | 135.44 | 165.59 |
Gain (Loss) on Sale of Investments | 32.92 | -10.3 | 6.31 | -0.86 | 1.61 | -1.1 |
Gain (Loss) on Sale of Assets | -1.27 | -0.93 | -0.39 | - | - | - |
Asset Writedown | 0.49 | -14.36 | -3.97 | -1.85 | -1.11 | -2.06 |
Other Unusual Items | 2.91 | 2.95 | 3.58 | 7.01 | 2.49 | 2.41 |
Pretax Income | 89.33 | 18.21 | 128.54 | 202.46 | 138.44 | 164.83 |
Income Tax Expense | 13.37 | 1.81 | 16.36 | 25.15 | 18.24 | 23.78 |
Net Income | 75.96 | 16.41 | 112.18 | 177.31 | 120.2 | 141.05 |
Net Income to Common | 75.96 | 16.41 | 112.18 | 177.31 | 120.2 | 141.05 |
Net Income Growth | 302.42% | -85.38% | -36.73% | 47.51% | -14.78% | -3.20% |
Shares Outstanding (Basic) | 90 | 91 | 92 | 86 | 69 | 69 |
Shares Outstanding (Diluted) | 90 | 91 | 92 | 86 | 69 | 69 |
Shares Change (YoY) | -1.75% | -0.88% | 6.83% | 25.31% | -0.17% | 2.00% |
EPS (Basic) | 0.84 | 0.18 | 1.22 | 2.06 | 1.75 | 2.05 |
EPS (Diluted) | 0.84 | 0.18 | 1.22 | 2.06 | 1.75 | 2.05 |
EPS Growth | 309.61% | -85.25% | -40.78% | 17.71% | -14.63% | -5.09% |
Free Cash Flow | -92.96 | -58.25 | 53.15 | 101.08 | 118.98 | 101.16 |
Free Cash Flow Per Share | -1.03 | -0.64 | 0.58 | 1.17 | 1.73 | 1.47 |
Dividend Per Share | 0.091 | 0.091 | 0.600 | 0.580 | 0.400 | 0.700 |
Dividend Growth | -84.83% | -84.83% | 3.45% | 45.00% | -42.86% | -7.90% |
Gross Margin | 16.85% | 18.96% | 38.44% | 44.58% | 39.77% | 47.12% |
Operating Margin | -1.40% | -2.13% | 18.98% | 27.94% | 26.27% | 34.12% |
Profit Margin | 17.28% | 3.82% | 22.93% | 31.20% | 23.04% | 29.58% |
Free Cash Flow Margin | -21.15% | -13.56% | 10.86% | 17.79% | 22.81% | 21.21% |
EBITDA | 35.59 | 38.69 | 148.89 | 210.37 | 183.15 | 196.29 |
EBITDA Margin | 8.10% | 9.01% | 30.43% | 37.02% | 35.11% | 41.16% |
D&A For EBITDA | 41.74 | 47.85 | 56 | 51.61 | 46.11 | 33.58 |
EBIT | -6.15 | -9.16 | 92.89 | 158.77 | 137.04 | 162.71 |
EBIT Margin | -1.40% | -2.13% | 18.98% | 27.94% | 26.27% | 34.12% |
Effective Tax Rate | 14.97% | 9.92% | 12.73% | 12.43% | 13.18% | 14.43% |
Revenue as Reported | 439.57 | 429.47 | 489.29 | 568.21 | 521.7 | 476.85 |
Advertising Expenses | - | - | - | 1.19 | - | - |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.